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Summary
PT9K/129G, a nontoxic mutant of pertussis toxin (PT) obtained by genetic manipulation, has
been shown in animal models to be a promising candidate for new vaccines against whooping
cough. To assess the safety and the immunogenicity of PT-9K/129G in humans, a pilot study
has been performed in adult volunteers. The protein was found to be safe, capable of inducing
high titers of toxin-neutralizing antibodies, and capable of generating immunological memory.
In fact, vaccination caused an increase of cell-mediated response to PT, PT9K/129G, S1 subunit,
and B oligomer, indicating that memory T cells are induced by the vaccine. Since PT-9K/129G
is mitogenic for T lymphocytes in vitro, it was investigated whether this activity is also present
in vivo. No variation was observed in the proportion of T cells (CD3'), T helper cells (CD4+),
and cytotoxic T cells (CD8+), as well as in that of other lymphoid populations, by FACS
analysis. Interestingly, no thorough correlation was foundbetween humoral and cellular responses.
In one case, a very high cellular response was present in absence of detectable antibodies, suggesting
that the antibody response, which is the only parameter measured in most clinical trials, may
not give a complete picture of the response induced by a vaccine.
A
though the conventional vaccine against whooping
cough, composed of whole Bordetellapertussis bacterial
cells, is very efficacious in preventing disease, it is not widely
used, because immunization with this vaccine is associated
with an excessive frequency of local and systemic side effects
(1-3). As a result, pertussis is responsible for >60 million
cases and more than half a million deaths each year (4). With
the aim ofdeveloping saferand less reactogenic vaccines, many
B. pertussis antigens have been purified and tested for safety
and efficacy in animal models (5) and human clinical trials
(6, 7). As anticipated by Pittman many years ago (8, 9), the
results have shown that vaccines containing chemically de-
toxified pertussis toxin (PT),1 either alone or combined with
other antigens, are less reactogenic and can prevent children
from having severe disease with an efficacy similar to that
of the whole cell vaccine (7, 10). In spiteofthe efficacy shown
in the clinical trial, acellular vaccines containing PT have not
yet been licenced, because there are still doubts about their
safety and their mechanism of protection. In fact, during a
1 Abbreviations used in this paper. CHO, Chinese hamster ovary; FHA,
filamentous hemagglutinin; PT, pertussis toxin; PTA, PBS containing
0.05% Tween 20 and 0.02% sodium azide.
large scale clinical trial carried out in Sweden, the chemically
detoxified PT showed reversion to toxicity (11). Furthermore,
no correlation was found between the level of antibodies
against PT and protection from disease (7). To solve the
problem of reversion to toxicity, we have developed an alter-
native method to detoxify PT By means of genetic manipu-
lation, we have modified two codons in the gene of PT and
obtained a B. pertussis strain that secretes a PT molecule (PT
9K/129G) naturally devoid of toxicity (12). This molecule
is an idealcandidate for a new vaccine against whooping cough
since it does not require chemical treatment . Moreover, it
cannot revert to toxicity and retains the natural B and T cell
epitopes of PT, which may be lost during chemical detoxifi-
cation. In addition, PT9K/129G retains other properties of
PT such as the ability to bind the receptors on eukaryotic
cells and to be mitogenic for T cells that are not present in
chemically detoxified molecules. After extensive studies in
animal models, which have shown that PT9K/129G is non-
toxic, immunogenic, and is able to protect mice from the
infection with virulent H pertussis (13), we have tested PT-
9K/12G in human adult volunteers. Immunization with this
antigen, which binds eukaryotic cell receptors and, at high
doses, is mitogenic for T cells, raises questions never encoun-
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Volume 172 September 1990 861-868teredbefore with conventional vaccines. To answer theseques-
tions, the clinical trial was designed not only to determine
by conventional methodsthesafety and theimmunogenicity
of the candidate vaccine, but also to address the in vivo role
of the T cell mitogenicity, and to find new parameters that
might correlate with immunity against pertussis.
Materials and Methods
Subjects andVaccination Schedule.
￿
29 healthyadult volunteers of
both sexes, 25-58 yr of age, recruited from Sclavo personnel, were
randomly attributed to receive, in double-blind tests, PT-9K/129G
or aplacebo. All thevolunteers hadlowanti-PTantibody titer(<20
EU/ml). 18 subjects received intramuscularly one dose of 0.5 ml
of vaccine; 11 subjects received a placebo. After 6 wk, 17 subjects
ofthe vaccine group andnine oftheplacebo groupreceived, respec-
tively, a second dose ofvaccine or placebo with thesame procedure
used for thefirst injection. Two subjects of the placebo groupand
oneofthevaccine group were not available when the second dose
was administered, and thereforereceived only one dose. Informed
consent was obtained from each volunteer. The protocol was ap-
proved by the New Drug Committee of the Italian Ministry of
Health.
Vaccine.
￿
The acellular pertussis vaccine PT-9K/129G (lot no.
D5/FA), prepared on June 22, 1989, and the placebo vaccine (lot
no. 1/89S) were prepared at Sclavo Laboratories (Siena, Italy). Each
0.5-mlsingle-dose vial ofvaccine contained15 pg ofPT9K/129G,
0.05 mg of thimerosal, and 0.5 mg ofaluminum hydroxide. Each
0.5-ml single-dose vial of placebocontained0.05 mg of thimerosal
and 0.5 mg of aluminum hydroxide.
SafetyAssessment.
￿
Donors were monitored foradverse reactions
and specific immune responses, as shownin Table 1. Bloodsamples
foranalysis ofredandwhitebloodcells, platelet count, hemoglobin
level, hematocrit, glucose, urea, creatinine, SGOT, SGPT, y GT,
IgE, and insulin (fasting values) were obtained before each injec-
tion andafter3 d (also after 1 mo for IgEand insulin only). Body
temperature was measured before each injection, after 6 and 24
h; injectionsites were inspecteddailyfor3 d aftereach administra-
tion by a physicianto monitor thepresence of local reactions (ery-
thema, induration, pain). A questionnaire was givento each volun-
teer on which to record reactions for a period of 2 wk.
Table 1.
￿
Protocol for Clinical and Laboratory Assessment of the Response Induced by 9KI129G PT Vaccine
Response
Local reactions (pain, erythema, induction)
Systemic reactions (>37.5°C)
Leukocyte number
Leukocyte markers
Insulin, glucose`
Antibodies
Cellular immunity
862
+3 +4 +30 +42 +43 +44 +45 +72
Injection I was given on day + 1, and injection 11 was given on day + 42.
" Fasting values.
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FACS Analysis.
￿
Phenotypic analysis of whole blood cells was
performed by direct immunofluorescence on a FACS (FACstar;
Becton Dickinson& Co., Erembodegem, Belgium). Thefollowing
PE- or fluorescein-conjugated mAbs were used: a-CD3 (OKT3);
a-CD4 (OKT4) (Ortho Diagnostic Systems Inc., Raritan, NJ);
ot-CD8 (Leu-2a); a-CD25 (IIL2R); a-CD19 (Leu-12); ot-CD23
(Leu-20); a-CD14 (Leu-M3); and ot-CD57(Leu-7) (Beckton Dick-
inson&Co.), as well as ct-y/S receptor (TCR-S1) (T Cell Sciences,
Cambridge, MA) at appropriate dilution.
Antigens.
￿
Wild-typePT andthenontoxic mutant PT9K129G
were purified from theculture supernatants ofthewild-type strain
B. pertussis W28 and of the recombinant strain B. pertussis W28-
9K/129G (12), by Affi-Gel blue absorption and fetuin-sepharose
affinity chromatography (14). B oligomer waspurified by the same
method from the B, pertussis strain W28-8D/9G double mutant,
which secretes into the culture medium only the B oligomer of
PT (15). Subunit S1 of PT was expressed in Escherichia coli and
purified as previously described (16). Filamentous hemagglutinin
(FHA) waspurified as describedby Cowell et al. (17). All antigens
used were >98% pure.
Chinese Hamster Ovary (CHO) Cell Toxin Neutralization
Assay. Toxin-neutralizing antibodies inducedby vaccination were
tested by the CHO cell assay (18). Briefly, sera from volunteers
obtained after vaccination with one or two doses of PT9K/129G
were diluted directly in the wells of flat-bottomed microplates
(Costar, Cambridge, MA) in 25 ul of DME (Flow Laboratories,
McLean, VA). Purified wild-type PT (120 pg) in 25 141 of DME
(Coulter Immunology, Hialeah, FL) was added to each well, and
the plates were incubated for 3 h at 37°C. After the incubation
period, 0.2 ml of DME containing 10° CHO cells, previously
treated with 1 mg/ml of trypsin, was added to each well and in-
cubated for 48 h at 37°C in atmosphere of 5% COa. As positive
control, theclustering effect of PT alonewas titered in each plate.
Neutralizing titers were expressed as thereciprocal of the highest
serum dilution causing complete inhibition of the clustering ac-
tivity induced by the native toxin. The US. Reference Pertussis
Antiserum (human)containing 640neutralizing units(NT), kindly
provided by the Center forDrugs and Biologics (Bethesda, MD),
was used as a standard.
ELISA.
￿
The ELISAmethod was performed as previously de-
scribed forguinea pig sera (13). Wellsofflat-bottomedpolystyrene
microtest plates (DynatechLaboratories, Inc., Alexandria, VA) were
Daycoated with 100 ul of PBS, pH 7.4, containing 1 p,g of purified
PT or FHA. The coating was performed for 2 h at 37°C and over-
night at 4°Cin a humidified chamber. The coatingbuffer was aspi-
rated, and wellswere washed with 200 141ofPBS containing 0.05%
Tween 20 and0.02% sodium azide (PTA). To minimize nonspecific
adsorption of serumproteins to the plastic, wellswere coated with
200 1AI of a blocking solution consisting of 1% BSA in PBS, and
then incubated for 2 h at 37°C. Plates were then washed three
times in PTA, and 200,ul of fivefold diluted test serum were added
to the wells. The U.S. Reference Pertussis Antiserum (human) con-
taining 200 ELISA units per ml of IgG anti-PT and 200 EU/ml
anti-FHA, kindly provided by the Center for Drugs and Biologics,
was used as a standard. Afterincubation at 37°C, plates were washed
three times with PTA, and a conjugate ofanti-humanIgG alkaline
phosphatase was added. Plates were then incubated at 37°C and
washed threetimes with PTA.Finally, 100 p,l ofp-nitrophenyl phos-
phate substrate (Sigma Chemical Co., St. Louis, MO) (1 mg/ml
in 1 M diethanolamine, pH 9.8) containing 1 MM MgC12, was
added to each well. The enzyme-substrate reaction, which devel-
oped at room temperature, was stopped after 30 min, and the OD
of the samples was measured at 405 nm against blank (substrate
in diethanolamine, pH 9.8)on a Titertek Multiskan (Flow Labora-
tories, Inc.). Controls for each plate included wells with serum
samples but no antigen, and wells with antigen but no serum
samples. Each serum sample was tested in duplicate, and absor-
bance values were averaged. The calculation of the ELISA anti-
body units in the test samples was determined according to the
U.S. Reference Pertussis Antiserum.
Proliferation Assays.
￿
Fycoll-Hypaque (Pharmacia Fine Chemicals
AB, Uppsala, Sweden)-separated PBMC were incubated (105
cells/well) for 3 d with PHA and 6 d with different antigen con-
centrations in flat-bottomed Cluster 96 plates (Costar). PT-9K/129G
and B oligomer were heat inactivated (at 100°C for 45 min) to
eliminate their mitogenic effect (19). The culturemediumwas RPMI
1640 (Gibco Laboratories, Paisley, Scotland) supplemented with
L-glutamine (2 mM), 1% nonessential amino acids, 1% sodium
pyruvate, 50 ug/ml gentamycin, 5 x 10-5 M 2-ME, and 10%
pooled human AB serum. All assay cultures were pulsed for the
last 16-18 h with 1 gCi of ['H]thymidine (sp act, 185 GBq/mmol;
Amersham International, Amersham, UK) . Cells were then har-
vested on glass fiber filters with a cell harvester (Skatron, Lier,
Norway), and incorporated radioactivity was determined byliquid
scintillation counting. Results ofproliferation assays are presented
as the mean counts per minute of triplicate cultures.
Statistical Analysis.
￿
The calculation of the ELISA antibody units
was based on the parallel line bioassay procedure previouslydescribed
using an ELISA unitage calculation program distributed by the Lab-
oratory of Pertussis, Center for Drugs and Biologics (20). An in-
crease in ELISA units of more than mean negative controls plus
3 SD was arbitrarily considered as a significant level ofanti-PT and
anti-FHA antibodies.
Results
Safety.
￿
A complete absence of typical adverse reactions,
either local or systemic, was observed after the first dose of
vaccine or placebo. After the second dose, 2 of 17 vaccinees
had mild local pain, erythema, and induration, while only
one of nine volunteers receiving the placebo had local pain.
Hematological, clinical chemistry, insulin, and IgE values did
not show any significant variation. No difference in leuko-
cyte numbers or leukocyte population proportions was ob-
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served between the two experimental groups (datanot shown).
Thus, these results in humans are similar to the animal studies,
where the PT9K/129G mutant was safe and unable to in-
duce the leukocytosis that is typically observed with wild-
type PT (12, 13).
Mitogenicity.
￿
Since it was observed that the mutant PT
9K/129G maintains the in vitromitogenic activity ofPT (13),
a careful study was carried out with four vaccine and two
placebo donors to clarify whether lymphoid subpopulation
can be affected in vivo by the vaccine. Fig. 1 shows that either
at 3 or 29 d after the first vaccine administration, the propor-
tion of total T cells (CD3) or that of the Th (CD3/CD4)
and T cytotoxic (CD3/CD8) subpopulation is almost iden-
tical. Similarly, the number of B cells (CD19), cells of the
monocyte-macrophage series (CD14), and NK cells (CD57)
remained the same after vaccination. Furthermore, neither
activationmarkers, such as CD25 for T lymphocytes or CD23
for B lymphocytes, nor the proportion ofT cellsbearing the
.y/6 receptor, changed after treatment (Fig. 1). It seems, there-
fore, that in vivo the mitogenic effect of PT9K/129G does
not play any relevant role.
Humoral Responses.
￿
Total antibodies against PT were evalu-
ated by ELISA and CHO cell toxin neutralization assays (Fig.
2, A and B, respectively). In both cases, 17 of 18 vaccinees
showed a statistically significant increase in titers after the
first vaccine administration. The titers were not further boosted
by the second injection. This was verified at an individual
level (Fig. 2) as well as at a group level (Table 2). Total lack
of correlation (r = 0.277, p = 0.266 for first injection; and
r = 0.191,,p = 0.480 for second injection) was observed be-
tween the two tests. Interestingly, a modest increase in anti-
body titer against FHA was observed by ELISA in vaccinees
(Table 2). One of the vaccinees (V2) did not show any
significant increase in antibody titer against PT (Fig. 2).
CellularResponses.
￿
We have previously shown that donors
that have acquired immunity against pertussis from the dis-
ease are able to express cellular responses to R pertussis an-
tigens (20), and that the cellular immunity against PT may
be against the subunit S1 or B oligomer (19). In this study,
we have investigated whether immunization with the genet-
ically inactivated PT molecule elicits a similar cell-mediated
response. Fig. 3 shows the results obtained with two repre-
sentative donors. After vaccination, cell-mediated responses
are increased against PT-9K/129G, wild-type PT, as well as
against whole inactivated Rpertussis. Furthermore, the results
suggest that immunity is directed against both the S1 subunit
and the other subunits forming oligomer B. No modification
of responsiveness to tetanus toxoid or PHA was observed.
Almost all vaccinees tested did not possess celular immunity
against R pertussis antigens at day +1 (Fig. 4 A) and con-
verted to significant proliferative values at day +30 (Fig. 4
B). The magnitude of proliferative response to PT-9K/129G
or wild PT can, however, differ from one donor to another
(Fig. 4 B). In general, the highest proliferative responses against
PT were observed in individuals with high antibody titers
against this antigen. One exception was represented by donor
V2. In fact, after repeated tests, this donor always showedstrong proliferative responses in the absence of specific anti-
bodies against IT. Interestingly, this donor showed the same
pattern of response, i .e ., high proliferative response and very
low antibody titer, even in response to tetanus toxoid (data
not shown) . On the other hand, donor V1 was able to pro-
duce high titers of antibody in spite ofthe very low prolifer-
ative response. It can be concluded that PT9K/129G vaccine
is in general able to induce both humoral and cellular responses,
even though a direct correlation between the two cannot be
observed .
Discussion
We have described the first experience ofhuman immuni-
zation with aFT molecule that has been inactivated by genetic
manipulation . Inoculation ofhumans with such a molecule
has allowed us not only to ask whether it is safe, immuno-
genic, and therefore suitable for vaccine development, but
also to ask other questions regarding the in vivo relevance
of the mitogenic activity ofPT and the immunogenicity of
native molecules that, unlike the currently used vaccines, are
not treated with chemical agents and still bind their receptors
on eukaryotic cells . In addition to the parameters that are
normally used to measure the immune response in vaccine
clinical trials, we have measured the cellularimmune response
to the antigen, a parameter that is thought to be the in vitro
correlate of the in vivo immunological memory. Interestingly
enough, we have found that humoral and cellular responses
do not necessarily correlate . This finding might be impor-
tant to explain why no correlation has been found between
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Figure 1 .
￿
Phenotypic analysis
ofPBMC from four vaccinees
(V11, V14, V20, and V21) and
two placebos (P7 and P16) . The
analysis was performed before
immunization (day +1), and 3
(day +4) and 29 (day +30) d
after.
immune response and susceptibility to the disease in those
vaccine trials where only antibody response has been tested (7) .
Safety .
￿
PT9K/129G vaccine did not induce significant ad-
verse reactions and did not cause any change of the parameters
tested, including the leukocyte, insulin, and IgE levels that
are usually altered by IT (21) . This results shows that the
genetically detoxified PT9K/129G can be safely used for
human immunization and confirms the results previously ob-
tained in animal models (13) .
T Cell Mitogenicity .
￿
Several bacterial toxins produced by
Staphylococcus aureus are potent T cell mitogens (22, 23) . In
some cases, their mitogenicity may be the cause of toxicity
(24, 25) . PT is a poor T cell mitogen and, to give a mito-
genic effect in vitro, it requires doses that are -103-106
times higher than those of staphylococcal enterotoxins SEA,
SEB, or TSST1 . In fact, the mitogenic dose of TSST1 is
1 pg/ml (25), 1 ng/ml for SEA and SEB (26), and 1 p,g/ml
for PT (13) . So far, the role in pathogenicity of the mito-
genic effect of PT has never been investigated, because the
toxicity of PT has always been attributed to the enzymatic
activity ofthe S1 subunit . The availability ofthe PT9K/129G
mutant, devoid ofenzymatic activity, but still mitogenic, has
allowed us to investigate the in vivo role of the mitogenic
properties ofPT We have previously shown that in micePT
9K/129G does not cause any local or systemic effect (13) .
In this study, we have shown, through FACS analysis, that
in humans the total number and subpopulation proportions
of T, B, and NK cells, and monocytes remain unaltered after
immunization with PT9K/129G. Furthermore, activation
markers, such asMR (CD25) and lymphokine IgE receptorTable 2.
￿
Serum Antibody Responses in Adult Volunteers Receiving Placebo or PT-9K/129G Vaccine
Figure 2 .
￿
Antibody titers of volunteers mea-
sured by ELISA (A) and by CHO neutralizing
test (B) . Assays were performed before immu-
nization (day +1), 29 d after the first immu-
nization (day +30), and 28 d after the second
immunization (day +72) . Values are expressed
in ELISA units or CHO neutralizing units. p,
placebo; v, vaccine.
' p < 0.01 vs . day 0 value .
tp 4 0.05 vs . day 0 value .
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Titer Day
Placebo
Geometric mean
(95% confidence
interval)
Stimulation
index
(vs . day + 1)
Vaccine
Geometric mean
(95% confidence
interval)
Stimulation
index
(vs . day +1)
Neutralizing titer (U in CHO assay) +1 12.8 (7 .5-21 .6) 13 .6 (8.6-21.5)
+30 12.8 (6.7-24.9) 1 .0 1,810.2 (737.0-4,446 .0)" 133
+72 11.7 (5 .9-23.0) 0.9 1,974 .0 (820.1-4,751.4)' 145
Antibody titer anti-PT (Elisa U) +1 6.5 (3.5-12.2) 6.7 (4.6-9.8)
+30 8.1 (4 .2-15.5) 1 .2 496.5 (199.9-1,233.3)' 74
+72 7.9 (4.5-13.9) 1 .2 522.4 (216 .8-1,258.6)' 78
Antibody titer anti-FHA (Elisa U) +1 9.4 (4 .3-20.7) 12.7 (7.5-21 .6)
+30 9.9 (4.7-20.9) 1 .0 85 .1 (54 .9-131 .7)' 6.7
+72 8.4 (4.1-17.3) 0.9 57.7 (39.1-85.5)t 4.5866
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Figure 3 .
￿
Proliferative re-
sponses of PBMC from one vac-
cinee and one placebo against
PT, PT-9K/129G, R pertussis
cells, subunit Sl, and B
oligomer of PT. Tetanus toxoid
and PHA were also tested as
controls. The results shown for
the two individuals (P16 and
V11) are representative of those
obtained with the other subjects
(seven vaccinees and two
placebos) that have been tested .
Proliferation to the subunit S1
and to the B oligomer at day
+1 were not done, since no re-
sponse was observed with PT.
Figure 4.
￿
Proliferative responses to wild-
type PT and PT-9K/129G in volunteers be-
fore (A) and 29 d after immunization (B) .
Proliferation on days +1 and +30 was not
measured in all subjects but only in five
placebos and 13 vaccinees that agreed to
give larger samples of blood . On day +72,
the cellular response, measured in two
placebos and four vaccinees, did not show
significant changes from day +30.(CD23), were not increased by vaccination. Similarly, the
proportion ofT cellsbearing ,y/6 receptors, a cell subpopu-
lation often reported to be increased during bacterial infec-
tions (27), remained unchanged. Based on this fact, it seems
reasonable to conclude that PT9K/129G does not induce in
vivo any nonspecific lymphocyte activation. Very likely, the
mitogenic activity of FT is just a side activity of receptor
binding and does not play an active role in pathogenesis, as
in the case of the staphylococcal toxins.
Humoral Response.
￿
One vaccine injection was capable of
inducing high titers of antibodies specific for PT with strong
neutralizing activity. Since the use of U.S. Reference Pertussis
Antiserum in our ELISA and CHO tests allows reasonable
comparison with previous studies, it can be concluded that
15 hg ofPT9K/129G induces a humoral response higher than
that obtained using 50 or 25 Fcg ofchemicallydetoxified FT
(28, 29). This confirms in vivo with humans that genetic
detoxification maintains the natural epitopes of the protein
that are lost or altered with chemical detoxification (L. Nen-
cioni, unpublished data) . The second dose ofvaccine did not
cause any further increase of humoral responses, indicating
that all adult volunteers had been previously exposed to B.
pertussis and consequently gave a secondary response to the
first immunization. Surprisingly, it was found that PT-9K/
129G preparation, obtained by affinity chromatography ac-
cording to Sekura (14),can induce in humans antibodies against
FHA. A subsequentcareful analysis by Western blot revealed
that FHA traces (<0.1%) contaminated the vaccine prepara-
tion. Since the methods used throughout this study prove
the specificity of the anti-PT response, this last result does
not impair the overall conclusion about the effectiveness of
the genetically inactivated toxoid, but rather, it provides fur-
ther experimental evidence that PT9K/129G can be included
in a multi-antigenic vaccine composed of PT together with
FHA and 69K, as suggested by several health authorities as
the final acellular vaccine against whooping cough.
Cellular Immunity. Although antibodies are usually
thought to play a major role in immunity against noninva-
sive bacterial infections, it is still a matter of debate which
immune mechanisms are more important in protection against
whooping cough. The recent finding in the Swedish clinical
trial that the presence ofanti-PT antibodies did not correlate
withprotection (7) may suggest that additionalimmune mech-
anisms such as cellular immunity may be important. We have
previously studied the human T cell responses against Bor-
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